Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
NCT00163306 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200
Last updated 2012-05-07
Summary
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the esophagus. GERD is one of the most common medical disorders, with estimates of up to 50% of adults reporting symptoms related to gastric reflux. Proton pump inhibitors (PPI) such as pantoprazole can relieve symptoms of GERD in a large proportion of patients.
When refluxed stomach acidic content touches the lining of the esophagus, it causes a burning sensation in the chest or throat. This sensation is often referred to as heartburn. Some patients have symptoms of GERD without visible destruction of the tissue surface (no visible changes by endoscopic examination).
The aim of the study is to evaluate the effect of pantoprazole on the complete remission of GERD. Complete remission is defined as endoscopically confirmed healing and symptom relief after a maximum of 12-week treatment period. Pantoprazole will be administered once daily in the morning. Endoscopy will be performed at the start of the study, and then as required after 4, 8, or 12 weeks. The study will provide further data on safety and tolerability of pantoprazole.
Conditions
- Gastroesophageal Reflux
Interventions
- DRUG
-
Pantoprazole
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Hartmut Heinze, MD · Altana Pharma AG, D-78467 Konstanz, Germany, [email protected]
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-05-31
Countries
- Austria
- Germany
- Hungary
- Poland
Study Locations
More Related Trials
-
Pantoprazole 20/40 mg in the Treatment of Symptomatic Reflux Disease With Focus on Sleep Disorders
NCT00830115 ·Status: COMPLETED
-
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
NCT00365300 ·Status: COMPLETED ·Phase: PHASE3
-
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
NCT00703534 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)
NCT00300755 ·Status: COMPLETED ·Phase: PHASE3
-
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
NCT00394472 ·Status: COMPLETED ·Phase: PHASE2
-
Role of Mosapride in Patients With Gastroesophageal Reflux Disease
NCT00729339 ·Status: COMPLETED ·Phase: PHASE4
-
The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
NCT01404832 ·Status: TERMINATED ·Phase: PHASE4
-
Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)
NCT00868296 ·Status: COMPLETED ·Phase: PHASE3
-
Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US
NCT00795093 ·Status: COMPLETED
-
Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing
NCT00537732 ·Status: TERMINATED ·Phase: PHASE4
-
An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients
NCT01370863 ·Status: TERMINATED ·Phase: PHASE2
-
Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy
NCT03596476 ·Status: RECRUITING ·Phase: NA
-
A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
NCT01043185 ·Status: COMPLETED ·Phase: PHASE2
-
What is the Predictive Value of the Reflux Impact Scale
NCT00536328 ·Status: TERMINATED
-
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)
NCT01161602 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD
NCT00362609 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
NCT00730665 ·Status: TERMINATED ·Phase: PHASE2
-
Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD
NCT00634023 ·Status: COMPLETED
-
Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
NCT00171483 ·Status: COMPLETED ·Phase: PHASE3
-
Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy
NCT00170001 ·Status: COMPLETED ·Phase: NA
-
An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
NCT00557401 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease
NCT07160790 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease
NCT02533349 ·Status: UNKNOWN ·Phase: PHASE3
-
A Prospective, Observational Study of the PPI Non-responder
NCT03282084 ·Status: WITHDRAWN
-
Measurement of Gastric Secretion by MRI Under Inhibition by ProtonPump Inhibitors in Healthy Subjects & in GERD Patients
NCT01212614 ·Status: COMPLETED ·Phase: NA